anti-amigo2 primary antibodies Search Results


rat monoclonal anti amigo2  (Proteintech)
93
Proteintech rat monoclonal anti amigo2
Rat Monoclonal Anti Amigo2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-amigo2+primary+antibodies/AMIGO2+Antibody/pm40998908-213-31-41
Average 93 stars, based on 1 article reviews
rat monoclonal anti amigo2 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
amigo2  (Elabscience Biotechnology)
94
Elabscience Biotechnology amigo2
Transcriptional expression and pathological stage analysis of AMIGO family members in PAAD using GEPIA2 database. (A-B) Comparison of AMIGO1, <t>AMIGO2</t> and AMIGO3 mRNA expression levels between PAAD and normal pancreatic tissues. (C) Expression levels of AMIGOs across different tumor stages in PAAD patients.
Amigo2, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-amigo2+primary+antibodies/AMIGO2+Polyclonal+Antibody/pmc12825146-84-7-9
Average 94 stars, based on 1 article reviews
amigo2 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Transcriptional expression and pathological stage analysis of AMIGO family members in PAAD using GEPIA2 database. (A-B) Comparison of AMIGO1, AMIGO2 and AMIGO3 mRNA expression levels between PAAD and normal pancreatic tissues. (C) Expression levels of AMIGOs across different tumor stages in PAAD patients.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: Transcriptional expression and pathological stage analysis of AMIGO family members in PAAD using GEPIA2 database. (A-B) Comparison of AMIGO1, AMIGO2 and AMIGO3 mRNA expression levels between PAAD and normal pancreatic tissues. (C) Expression levels of AMIGOs across different tumor stages in PAAD patients.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques: Expressing, Comparison

Prognostic value of AMIGO family in pancreatic adenocarcinoma (PAAD) patients. (A) Relapse-free survival (RFS) curves and (B) Overall survival (OS) of AMIGO1, AMIGO2 and AMIGO3 in PAAD.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: Prognostic value of AMIGO family in pancreatic adenocarcinoma (PAAD) patients. (A) Relapse-free survival (RFS) curves and (B) Overall survival (OS) of AMIGO1, AMIGO2 and AMIGO3 in PAAD.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques:

Genetic alterations, gene and protein interaction networks and co-expression analysis of AMIGO family members in pancreatic adenocarcinoma (PAAD). (A-B) Genetic alteration analysis of AMIGO1, AMIGO2 and AMIGO3 in PAAD patients using cBioPortal. (C) Gene-gene interaction (GGI) network of AMIGOs constructed by GeneMANIA. (D) Protein-protein interaction (PPI) network of AMIGOs generated using the STRING database. (E) Co-expression gene analysis of AMIGOs based on the intersection of top 1000 correlated genes, visualized using VENNY.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: Genetic alterations, gene and protein interaction networks and co-expression analysis of AMIGO family members in pancreatic adenocarcinoma (PAAD). (A-B) Genetic alteration analysis of AMIGO1, AMIGO2 and AMIGO3 in PAAD patients using cBioPortal. (C) Gene-gene interaction (GGI) network of AMIGOs constructed by GeneMANIA. (D) Protein-protein interaction (PPI) network of AMIGOs generated using the STRING database. (E) Co-expression gene analysis of AMIGOs based on the intersection of top 1000 correlated genes, visualized using VENNY.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques: Expressing, Construct, Generated

Functional enrichment analysis of AMIGO2 in pancreatic adenocarcinoma (PAAD) by using the DAVID platform. (A-C) Gene Ontology (GO) enrichment analysis of AMIGO2-related genes, categorized into biological processes (BP), cellular components (CC), and molecular functions (MF), respectively. (D) Top 20 GO terms enriched in AMIGO2 co-expressed genes. (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of AMIGO2-associated genes.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: Functional enrichment analysis of AMIGO2 in pancreatic adenocarcinoma (PAAD) by using the DAVID platform. (A-C) Gene Ontology (GO) enrichment analysis of AMIGO2-related genes, categorized into biological processes (BP), cellular components (CC), and molecular functions (MF), respectively. (D) Top 20 GO terms enriched in AMIGO2 co-expressed genes. (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of AMIGO2-associated genes.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques: Functional Assay

Correlation between AMIGO2 and EMT-related transcription factors in PAAD. (A) Protein expression of AMIGO2 in normal pancreatic tissues and PAAD tissues based on immunohistochemistry (IHC) images from the Human Protein Atlas (HPA). Representative IHC staining shows weak or absent AMIGO2 expression in normal pancreatic tissues (left) and stronger staining intensity in PAAD tissues (right). (B-G) Correlation analyses between AMIGO2 and key EMT-related transcription factors in TCGA-PAAD. Scatter plots show the Spearman correlation between AMIGO2 expression and ZEB1 (ρ = 0.27, p = 2.7 × 10⁻⁴), SNAI1 (ρ = 0.23, p = 1.8 × 10⁻³), SP1 (ρ = 0.40, p = 3.6 × 10⁻⁸), NFKB1 (ρ = 0.22, p = 3.8 × 10⁻³), RELA (ρ = 0.41, p = 1.8 × 10⁻⁸) and TWIST1 (ρ = 0.37, p = 4.1 × 10⁻⁷). (H) Correlation between AMIGO2 expression and immune cell infiltration across TCGA cancer types, including pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), and prostate adenocarcinoma (PRAD), analyzed using TIMER2.0 with tumor purity adjustment. The heatmap displays partial Spearman correlation coefficients across multiple immune deconvolution algorithms. (I) Correlation between AMIGO2 and CD274 (PD-L1) expression in TCGA-PAAD, analyzed using GEPIA2 (Spearman correlation). Scatter plot shows a significant positive correlation (R = 0.34, p = 3.9 × 10⁻⁶), indicating that AMIGO2-high tumors exhibit elevated PD-L1 expression.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: Correlation between AMIGO2 and EMT-related transcription factors in PAAD. (A) Protein expression of AMIGO2 in normal pancreatic tissues and PAAD tissues based on immunohistochemistry (IHC) images from the Human Protein Atlas (HPA). Representative IHC staining shows weak or absent AMIGO2 expression in normal pancreatic tissues (left) and stronger staining intensity in PAAD tissues (right). (B-G) Correlation analyses between AMIGO2 and key EMT-related transcription factors in TCGA-PAAD. Scatter plots show the Spearman correlation between AMIGO2 expression and ZEB1 (ρ = 0.27, p = 2.7 × 10⁻⁴), SNAI1 (ρ = 0.23, p = 1.8 × 10⁻³), SP1 (ρ = 0.40, p = 3.6 × 10⁻⁸), NFKB1 (ρ = 0.22, p = 3.8 × 10⁻³), RELA (ρ = 0.41, p = 1.8 × 10⁻⁸) and TWIST1 (ρ = 0.37, p = 4.1 × 10⁻⁷). (H) Correlation between AMIGO2 expression and immune cell infiltration across TCGA cancer types, including pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), and prostate adenocarcinoma (PRAD), analyzed using TIMER2.0 with tumor purity adjustment. The heatmap displays partial Spearman correlation coefficients across multiple immune deconvolution algorithms. (I) Correlation between AMIGO2 and CD274 (PD-L1) expression in TCGA-PAAD, analyzed using GEPIA2 (Spearman correlation). Scatter plot shows a significant positive correlation (R = 0.34, p = 3.9 × 10⁻⁶), indicating that AMIGO2-high tumors exhibit elevated PD-L1 expression.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques: Expressing, Immunohistochemistry, Staining

AMIGO2 promotes migration and invasion by inducing EMT in pancreatic cancer cells. (A) Western blot analysis of AMIGO2 protein levels in MiaPaCa-2 cells transfected with two independent AMIGO2 shRNAs (kd-AMIGO2 A1 and kd-AMIGO2 B2) compared with control cells. α-Tubulin served as a loading control. (B) Western blot analysis of EMT markers showing that AMIGO2 knockdown upregulated E-cadherin and downregulated Vimentin expression. α-Tubulin was used as an internal control. (C) Representative images of wound-healing assays performed in MiaPaCa-2 cells after AMIGO2 knockdown, captured at 0, 24, and 48 h. (D) Quantitative analysis of wound closure rates (%) in MiaPaCa-2 control and AMIGO2-silenced cells. (E) Representative images of Transwell invasion assays showing a reduced number of invading cells following AMIGO2 knockdown. (F) Statistical quantification of invaded cell area (%) based on Transwell assays. ***, p<0.01.

Journal: International Journal of Medical Sciences

Article Title: AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma

doi: 10.7150/ijms.121794

Figure Lengend Snippet: AMIGO2 promotes migration and invasion by inducing EMT in pancreatic cancer cells. (A) Western blot analysis of AMIGO2 protein levels in MiaPaCa-2 cells transfected with two independent AMIGO2 shRNAs (kd-AMIGO2 A1 and kd-AMIGO2 B2) compared with control cells. α-Tubulin served as a loading control. (B) Western blot analysis of EMT markers showing that AMIGO2 knockdown upregulated E-cadherin and downregulated Vimentin expression. α-Tubulin was used as an internal control. (C) Representative images of wound-healing assays performed in MiaPaCa-2 cells after AMIGO2 knockdown, captured at 0, 24, and 48 h. (D) Quantitative analysis of wound closure rates (%) in MiaPaCa-2 control and AMIGO2-silenced cells. (E) Representative images of Transwell invasion assays showing a reduced number of invading cells following AMIGO2 knockdown. (F) Statistical quantification of invaded cell area (%) based on Transwell assays. ***, p<0.01.

Article Snippet: Primary antibodies used in this study included: AMIGO2 (E-AB-10790, Elabscience), E-cadherin (R55-180, BD Biosciences), Vimentin (E-AB-22085, Elabscience), and α-Tubulin (T6199, Sigma-Aldrich).

Techniques: Migration, Western Blot, Transfection, Control, Knockdown, Expressing